237 related articles for article (PubMed ID: 2405486)
1. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
McQuade TJ; Tomasselli AG; Liu L; Karacostas V; Moss B; Sawyer TK; Heinrikson RL; Tarpley WG
Science; 1990 Jan; 247(4941):454-6. PubMed ID: 2405486
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.
Meek TD; Lambert DM; Dreyer GB; Carr TJ; Tomaszek TA; Moore ML; Strickler JE; Debouck C; Hyland LJ; Matthews TJ
Nature; 1990 Jan; 343(6253):90-2. PubMed ID: 1688646
[TBL] [Abstract][Full Text] [Related]
3. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
Dis Markers; 1990; 8(3):162-3. PubMed ID: 2125537
[No Abstract] [Full Text] [Related]
4. Maturation of human immunodeficiency virus particles assembled from the gag precursor protein requires in situ processing by gag-pol protease.
Ross EK; Fuerst TR; Orenstein JM; O'Neill T; Martin MA; Venkatesan S
AIDS Res Hum Retroviruses; 1991 May; 7(5):475-83. PubMed ID: 1873082
[TBL] [Abstract][Full Text] [Related]
5. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
Sei S; Yang QE; O'Neill D; Yoshimura K; Nagashima K; Mitsuya H
J Virol; 2000 May; 74(10):4621-33. PubMed ID: 10775598
[TBL] [Abstract][Full Text] [Related]
6. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication.
Venaud S; Yahi N; Fehrentz JL; Guettari N; Nisato D; Hirsch I; Chermann JC
Res Virol; 1992; 143(5):311-9. PubMed ID: 1480823
[TBL] [Abstract][Full Text] [Related]
8. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease.
Erickson-Viitanen S; Manfredi J; Viitanen P; Tribe DE; Tritch R; Hutchison CA; Loeb DD; Swanstrom R
AIDS Res Hum Retroviruses; 1989 Dec; 5(6):577-91. PubMed ID: 2692658
[TBL] [Abstract][Full Text] [Related]
9. Rational design of peptide-based HIV proteinase inhibitors.
Roberts NA; Martin JA; Kinchington D; Broadhurst AV; Craig JC; Duncan IB; Galpin SA; Handa BK; Kay J; Kröhn A
Science; 1990 Apr; 248(4953):358-61. PubMed ID: 2183354
[TBL] [Abstract][Full Text] [Related]
10. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.
Ashorn P; McQuade TJ; Thaisrivongs S; Tomasselli AG; Tarpley WG; Moss B
Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7472-6. PubMed ID: 2217178
[TBL] [Abstract][Full Text] [Related]
11. Antiviral agent based on the non-structural protein targeting the maturation process of HIV-1: expression and susceptibility of chimeric Vpr as a substrate for cleavage by HIV-1 protease.
Serio D; Singh SP; Cartas MA; Weber IT; Harrison RW; Louis JM; Srinivasan A
Protein Eng; 2000 Jun; 13(6):431-6. PubMed ID: 10877854
[TBL] [Abstract][Full Text] [Related]
12. The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles.
Park J; Morrow CD
J Virol; 1992 Nov; 66(11):6304-13. PubMed ID: 1383561
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles.
Karacostas V; Wolffe EJ; Nagashima K; Gonda MA; Moss B
Virology; 1993 Apr; 193(2):661-71. PubMed ID: 7681610
[TBL] [Abstract][Full Text] [Related]
14. Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine.
Wagner R; Fliessbach H; Wanner G; Motz M; Niedrig M; Deby G; von Brunn A; Wolf H
Arch Virol; 1992; 127(1-4):117-37. PubMed ID: 1456888
[TBL] [Abstract][Full Text] [Related]
15. [Interaction of gag polyprotein-precursors p55 and p48 with p160gag-pol during formation of virus-like particles of HIV-1 with recombinant strains of vaccinia virus].
Iordanskiĭ SN; Lideman LF; Chikova AK; Gibadulin RA
Vopr Virusol; 1997; 42(5):205-8. PubMed ID: 9424843
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins.
Cameron CE; Grinde B; Jentoft J; Leis J; Weber IT; Copeland TD; Wlodawer A
J Biol Chem; 1992 Nov; 267(33):23735-41. PubMed ID: 1331099
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles.
Park J; Morrow CD
Virology; 1993 Jun; 194(2):843-50. PubMed ID: 8503189
[TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.
el-Farrash MA; Kuroda MJ; Kitazaki T; Masuda T; Kato K; Hatanaka M; Harada S
J Virol; 1994 Jan; 68(1):233-9. PubMed ID: 8254733
[TBL] [Abstract][Full Text] [Related]
19. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.
Alteri E; Bold G; Cozens R; Faessler A; Klimkait T; Lang M; Lazdins J; Poncioni B; Roesel JL; Schneider P
Antimicrob Agents Chemother; 1993 Oct; 37(10):2087-92. PubMed ID: 8257128
[TBL] [Abstract][Full Text] [Related]
20. In vitro inhibition of HIV-1 proteinase by cerulenin.
Moelling K; Schulze T; Knoop MT; Kay J; Jupp R; Nicolaou G; Pearl LH
FEBS Lett; 1990 Feb; 261(2):373-7. PubMed ID: 1690152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
